Source: Annual Congress 2009 - Healthcare and treatment of COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
N. Berdnikova, D. Tsiganko, M. Averyianov (Moscow, Russian Federation). The study of influence of different bronchodilatators in the patients with exacerbation of chronic obstructive disease (COPD) and benign prostatic hyperplasia (bph). Eur Respir J 2009; 34: Suppl. 53, 3455

Member's Comments

No comment yet.

Related content which might interest you: The state of patients with chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2007; 30: Suppl. 51, 547s Year: 2007 Can chronic obstructive lung disease (COPD) criteria be used to manage bronchiectasis (BR) and obliterative bronchiolitis (OB) in children surviving severe lung infection? Source: Eur Respir J 2001; 18: Suppl. 33, 172s Year: 2001 Benefits of pulmonary rehabilitation (PR) in patients with chronic obstructive pulmonary disease (COPD) and interstitial lung disease (ILD) having the same dyspnoea severity Source: International Congress 2018 – What’s hot in rehabilitation in COPD and interstitial lung disease (ILD)? Year: 2018 Can we predict the outcomes of treatment of patients with severe exacerbation of chronic obstructive pulmonary disease (COPD)? Source: Eur Respir J 2001; 18: Suppl. 33, 241s Year: 2001 Next generation sequencing in lung adenocarcinoma of smokers with and without chronic obstructive pulmonary disease (COPD) Source: International Congress 2017 – Clinical research in lung cancer: new valuable results on lung cancer detection, prognostic biomarkers, and tyrosine kinase inhibitors Year: 2017 The influence of inhalation device for bronchodilators on the results of therapy in primary care patients with bronchial asthma (BA) and chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2008 - Asthma control or asthma severity Year: 2008 Longitudinal study of FEO1 as a criterion for bronchial obstruction in outpatients with chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2005; 26: Suppl. 49, 64s Year: 2005 The metabolic syndrome (MetS) in patients with chronic obstructive pulmonary disease (COPD) and its association with airway obstruction Source: Annual Congress 2012 - COPD is not a pulmonary disease alone Year: 2012 Bronchiectasis impact outcomes in patients with chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2008 - Microbiology and treatment of bronchiectasis and exacerbations of COPD Year: 2008 The relationship between fibroblasts and airway structure in patients with asthma and chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2001; 18: Suppl. 33, 148s Year: 2001 The safety of sputum induction in patients with exacerbation of severe and very severe COPD (chronic obstructive pulmonary disease) Source: Annual Congress 2008 - Organisation of care and management of COPD Year: 2008 Enalapril in the management of patients with chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2003; 22: Suppl. 45, 241s Year: 2003 Microbiological features of the indicators of bronchial asthma (BA) and chronic obstructive pulmonary disease (COPD) during remission Source: International Congress 2019 – Clinical aspects of airway diseases Year: 2019 Chronic obstructive pulmonary disease (COPD) patients with bronchiectasis: clinical features? Source: International Congress 2018 – COPD exacerbations and bronchiectasis Year: 2018 Is the severity of oxidative stress different in patients with end stage chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF) waiting for lung transplantation? Source: Annual Congress 2007 - Pathophysiology and assessment of COPD Year: 2007 Subpopulation structure of lymphocytes in patients with chronic obstructive pulmonary disease (COPD) during exacerbation and after treatment Source: Annual Congress 2008 - Microbiology and treatment of bronchiectasis and exacerbations of COPD Year: 2008 The characteristic of chronic renal dysfunction in patients with chronic obstructive pulmonary disease Source: International Congress 2016 – Biomarkers and phenotypes of COPD and comorbidities Year: 2016 Predictive factors for the incidence of lung cancer (LC) complicated in patients with chronic obstructive pulmonary disease (COPD) Source: International Congress 2019 – Advances in clinical management of COPD Year: 2019 Functional and inflammatory bowel diseases in patients with chronic obstructive pulmonary disease (COPD). Source: International Congress 2019 – Advances in clinical management of COPD Year: 2019 Lung volume response to bronchodilators is dependent on the stage of the disease in chronic obstructive pulmonary disease (COPD) patients Source: Annual Congress 2006 - COPD therapy Year: 2006